<DOC>
	<DOCNO>NCT02613039</DOCNO>
	<brief_summary>Oral contraceptive ( OCs ) ameliorate hyperandrogenism regulate menstrual cycle . To reduce androgenic side effect first- second-generation progestin , several new progestin derive progesterone spironolactone develop last decade . These progestin , drospirenone , cyproterone acetate NOMAC , design bind specifically progesterone receptor androgenic , estrogenic glucocorticoid action . However , OCs pronounce anti-androgenic effect likely induce sexual dysfunction , mainly hypoactive sexual desire disorder , highly impact patient partner 's quality life . Moreover , available data indicate OC use might increase adiposity adolescent might associate central redistribution body fat young woman Polycystic ovary syndrome ( PCOS ) without recognizable difference clinical anthropometric measurement , include body mass index waist circumference . In context , would worth evaluate effect combine OCs metabolic sexual health ( sexual desire , arousal , parameter sexual health ) , body image mood .</brief_summary>
	<brief_title>Oral Contraceptive Therapy Sexuality</brief_title>
	<detailed_description>Primary study objective Evaluation , sample female outpatient subject , effect oral contraceptive ( OCs ) sexual function distress , evaluate FSFI ( Female Sexual Function Index ) FSDS ( Female Sexual Distress Scale Revised ) questionnaire clitoris artery hemodynamic parameter . Secondary study objective Evaluation , sample female outpatient subject , effect OCs : - body image perception , evaluate BUT ( Body Uneasiness Test ) questionnaire ; - mood mental status , evaluate MHQ ( Middlesex Hospital questionnaire ) ; - hormonal metabolic parameter . Exploratory Objectives : evaluation relationship hormonal parameter , clinical score sexual function , body image , mood study population .</detailed_description>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<mesh_term>Progestins</mesh_term>
	<criteria>Female subject age =/ &gt; 18 year reproductive age . Capacity give consent study participation , adequately inform aim , benefit , risk , time motion study . Participation another clinical trial . Known suspected ( history ) malignancy chronic illness . Serious organic mental disease diagnose psychiatrist ( e.g. , major depression currently treat antidepressant medication ) suspect basis medical history and/or clinical examination . Conditions may affect compliance study . Contraindications therapy study drug hypersensitivity study drug ( active ingredient excipients formulation ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>oral contraceptive</keyword>
	<keyword>female sexuality</keyword>
</DOC>